(NRXS) NeurAxis, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NRXS) NeurAxis, Inc. Complete Analysis Pack
See the Bigger Picture
This NeurAxis, Inc. 4P's Marketing Mix Analysis outlines the company’s Product, Price, Place, and Promotion strategy and shows how those elements support positioning and sales; the page includes a real preview/sample of the analysis so you can evaluate format and content before buying. Purchase the full version to get the complete, ready-to-use report.
Product
IB-Stim
IB-Stim is NeurAxis, Inc.'s lead commercial product: a percutaneous electrical nerve field stimulation (PENFS) device used to help reduce functional abdominal pain tied to irritable bowel syndrome. In the 4P mix, it sits as the core Product, with a prescription-led, non-drug therapy profile that targets a defined patient group. Its value comes from offering a device-based option where pain and IBS symptoms can limit daily function.
Adolescents 11 to 18
The labeled group is ages 11 to 18, so NeurAxis positions this as a pediatric specialty therapy, not a broad adult device. That 8-year band sharpens targeting, prescriber education, and reimbursement focus. In the U.S., ages 10 to 19 are about 13% of the population, which keeps the market niche but clearly defined.
120-hour wear
IB-Stim is designed as a short treatment course, with the device typically worn for about 120 hours before removal. That limited wear time supports an office-start, home-wear workflow, so treatment begins in clinic and continues at home with less disruption. The 120-hour window is a clear product fit cue in NeurAxis, Inc.'s 4P mix because it keeps use simple and time-bound.
Non-drug therapy
NeurAxis, Inc. offers a nonpharmacologic, non-opioid therapy that gives patients an alternative to daily drug dosing for symptom relief. Its value is simple: treat pain-related symptoms without adding medicine burden, which matters for patients avoiding opioid risk or long-term medication use. FDA-cleared IB-Stim is used in patients ages 8 to 21 with functional abdominal pain linked to IBS.
- Non-drug pain management option
- Non-opioid, daily pill-free use
- Targets symptom relief, not masking
Clinician-supervised neuromodulation
NeurAxis sells a clinician-supervised neuromodulation device, so its product sits in medical care, not consumer health. Its strategy is narrow and clinical: treat gastrointestinal pain disorders such as functional abdominal pain and IBS-related symptoms through physician-guided use.
- Medical device, not wellness product
- Used under clinician supervision
- Focuses on GI pain disorders
- Competes in neuromodulation
NeurAxis IB-Stim: FDA-Cleared, Non-Drug IBS Pain Relief for Ages 8–21
IB-Stim is NeurAxis, Inc.'s core product: an FDA-cleared PENFS device for functional abdominal pain linked to IBS, used under clinician supervision. It is a non-drug, non-opioid therapy for ages 8 to 21 and is worn for about 120 hours, keeping treatment short and time-bound.
| Key fact | Data |
|---|---|
| Therapy type | PENFS device |
| Label age range | 8 to 21 |
| Wear time | 120 hours |
What is included in the product
Detailed Word Document
A concise, company-specific breakdown of NeurAxis, Inc.’s Product, Price, Place, and Promotion strategy for practical marketing analysis.
Editable Excel File
Simplifies NeurAxis, Inc.’s 4Ps into a clear snapshot that quickly relieves marketing analysis pain points.
Reference Sources
Lists primary, reputable sources to validate NeurAxis market, pricing, and competitive assumptions, speeding diligence and enabling fast verification of key claims.
Place
Hospitals
Hospitals are a key place for NeurAxis because the Company sells mainly to healthcare providers, and clinician-led use fits a device that needs referral, start, and follow-up in a supervised setting. Hospitals also help drive adoption through pain, GI, and pediatric care teams, so they matter for both initial placement and repeat use. In practice, the hospital channel supports diagnosis, training, and reimbursement tied to provider workflows.
Clinics
Outpatient clinics are a key channel for NeurAxis, Inc., especially in pediatric gastroenterology and pain management. They support repeat visits, which helps with device fitting, training, and follow-up. That matters because these care paths often need multiple touchpoints, not a one-time visit.
Physician offices
Physician offices are the gatekeeper for NeurAxis, Inc. because the product is prescribed, not sold on a shelf. Access depends on a clinician deciding the therapy fits the patient, so office education and adoption drive use. That makes the prescribing visit the key point where demand starts and sales can scale.
U.S.-based distribution
NeurAxis, Inc. is headquartered in Carmel, Indiana, and its distribution is centered in the United States. That fits its domestic, provider-focused sales model, where access to U.S. clinicians and care sites matters more than a broad global network. The U.S. base also keeps its commercial reach tightly aligned with local reimbursement and adoption patterns.
- Headquarters: Carmel, Indiana
- Commercial reach: U.S.-centered
- Sales model: provider-focused
Direct provider sales
NeurAxis, Inc. sells direct to healthcare providers, not consumers, which fits specialty medtech where hands-on training and reimbursement help matter most. This model keeps product placement controlled and supports adoption in clinics where provider education can drive use faster than broad consumer marketing.
- Provider-led sales fit specialty medtech
- Training improves clinical adoption
- Reimbursement support helps conversion
- Controlled placement protects brand use
NeurAxis Uses U.S. Providers to Drive Adoption
NeurAxis, Inc. places its products mainly through U.S. hospitals, outpatient clinics, and physician offices, where clinician-led prescribing, training, and follow-up happen. The Company is U.S.-centered from Carmel, Indiana, so access to provider workflows and reimbursement is the key path to use. Direct provider sales keep placement controlled and support adoption.
| Place | Role |
|---|---|
| Hospitals | Referral and follow-up |
| Clinics | Repeat visits |
| Physicians | Prescribing gatekeeper |
Full Version Awaits
NeurAxis, Inc. Reference Sources
The preview shown here is the actual NeurAxis, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.
Promotion
Healthcare provider marketing
NeurAxis, Inc. focuses promotion on doctors and care teams because its products are prescription medical devices, so trust and clinical buy-in drive use. That approach is aimed at hospital and clinic adoption, where care pathways are set and monitored. In the U.S., more than 6,000 hospitals and millions of outpatient visits make provider education the fastest route to scale.
Clinical evidence
NeurAxis’s promotion leans on clinical evidence because, in medtech, proof drives adoption. The Company’s IB-Stim is FDA-cleared for patients 8 to 21 with functional abdominal pain related to IBS, and its sham-controlled studies showed meaningful pain improvement, which helps support pediatric use and payer review. That data is the core sales asset, not branding.
Medical education
Medical education is a key promotion lever for NeurAxis, Inc. Training materials and clinician conversations explain how PENFS works and how IB-Stim is used in patients ages 11 to 18, which helps reduce adoption barriers in specialty practices. Clear use guidance also supports faster clinician onboarding and more confident referrals.
Professional meetings
Professional meetings are a standard promotion channel for NeurAxis, Inc. because they put the Company Name in front of pediatric gastroenterology and pain specialists where referrals and device trust are built. In 2025, peer-reviewed, face-to-face settings still matter most for device adoption, since specialist conferences often draw hundreds to thousands of clinicians and support peer-to-peer credibility.
- Targets pediatric GI and pain doctors
- Builds peer trust fast
- Fits medical device buying habits
Company communications
NeurAxis uses public company communications as promotion: SEC filings, press releases, and the corporate website keep the brand in view and support product awareness. These channels also reinforce clinical positioning, which matters in a market where investors track both growth and evidence. Latest investor updates and filings stay tied to each 10-K and 10-Q cycle.
- SEC filings build trust.
- Press releases drive visibility.
- Website supports clinical proof.
Clinician Training and Clinical Data Drive NeurAxis Adoption
NeurAxis promotes through clinicians, evidence, and investor channels. IB-Stim is FDA-cleared for ages 8 to 21, and training for ages 11 to 18 lowers adoption friction in pediatric GI and pain care. Peer-reviewed studies and conference outreach support trust, while SEC filings and press releases keep the Company Name visible.
| Channel | Role |
|---|---|
| Clinician training | Drives adoption |
| Clinical data | Builds trust |
| SEC filings | Supports awareness |
Price
No public list price
NeurAxis does not publicly post a consumer-style list price for IB-Stim, so there is no fixed sticker price to cite. As a specialty medical device, IB-Stim is typically sold through provider and payer channels, where contract terms and reimbursement shape the final net price. That makes pricing case-by-case, not retail.
Provider-based purchasing
NeurAxis, Inc. sells through hospitals and clinics, so price is set in B2B talks, not at a retail shelf. Terms can vary by account, with discounts, payment timing, and volume tied to each provider contract. That makes provider mix and reimbursement fit more important than a single list price.
Insurance reimbursement
Insurance reimbursement drives NeurAxis, Inc.'s price, because payer coverage and prior authorization decide access and what patients pay. The real selling price is tied to claim approval, not just the sticker price, so a denied claim can leave the patient facing the full cost. In 2025, this meant reimbursement wins mattered as much as product demand for volume growth.
Variable out-of-pocket costs
NeurAxis, Inc. faces variable out-of-pocket costs because patient cost exposure is not fixed. In 2025 Medicare Part B, the deductible is $257 and many covered items still leave patients paying 20% coinsurance, so the final bill can swing with plan rules and benefit stage.
Coinsurance changes the patient share.
Deductibles raise first-year costs.
Coverage rules can shift payment.
Specialty devices often vary by plan.
Value vs chronic drug therapy
NeurAxis, Inc. prices its therapy as a short, 5-day device treatment, not ongoing drug use, so buyers compare total episode cost, not monthly refill cost. The non-drug angle matters in functional abdominal pain, where chronic medication can add repeat pharmacy, follow-up, and adherence costs. That makes the value case about one treatment course versus a long therapy cycle.
- 5-day treatment, not chronic dosing
- Non-drug option for abdominal pain
- Value tied to episode cost
- Fewer refill-linked costs
NeurAxis IB-Stim Has No List Price—Coverage Drives Real Cost
NeurAxis, Inc. has no public list price for IB-Stim, so pricing is negotiated through provider and payer contracts. In 2025, patient cost depends on coverage; Medicare Part B had a $257 deductible and 20% coinsurance on many covered services. So the real price is the net reimbursed amount, not a shelf price.
| Price driver | 2025/2026 fact |
|---|---|
| List price | Not publicly posted |
| Medicare Part B deductible | $257 |
| Typical coinsurance | 20% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.